Study protocol for microneurographic investigation of nociceptor sensitisation in Fibromyalgia Syndrome. (MICRO-FMS)

The MICRO-FMS study protocol outlines an adaptive Bayesian microneurography investigation designed to precisely determine the prevalence of abnormal C-fibre nociceptor activity in Fibromyalgia Syndrome while minimizing patient burden through early futility assessment and optimized data collection methods.

The Gist

The Big Picture: Hunting for the "Ghost in the Machine"

Imagine your body's nervous system is like a massive, high-tech security network. Usually, the sensors (nerves) only send an alarm when something real happens, like a hot stove or a sharp pin.

In Fibromyalgia, however, the system is broken. It's like a security camera that keeps flashing red lights and screaming "INTRUDER!" even when the house is empty. This is called chronic pain.

The researchers at the University of Bristol want to find out exactly which sensor is broken. They suspect a specific type of tiny nerve fiber (called a CMi nociceptor) is acting like a "ghost in the machine"—firing off pain signals on its own, without any touch or injury.

The Problem: The "Needle in a Haystack" Problem

To find these broken sensors, scientists use a technique called microneurography.

• The Analogy: Imagine trying to listen to a single person whispering in a crowded, noisy stadium. You have to put a super-sensitive microphone (a tiny needle) right next to the nerve to hear it.
• The Challenge: This is hard work. It takes a long time, it can be uncomfortable for the patient, and finding the right nerve is like finding a needle in a haystack. In the past, studies only had a few people, so the results were shaky (like trying to guess the weather based on one day of data).

The Solution: A Smarter, Faster Hunt (The Bayesian Strategy)

This new study wants to fix the "small sample size" problem without making patients suffer longer than necessary. They are using a Bayesian Adaptive Design.

Here is the analogy:
Imagine you are a detective trying to solve a crime.

• Old Way (Frequentist): You decide to interview exactly 100 people no matter what. Even if the first 5 people say, "The crime never happened," you keep interviewing until you hit 100. This wastes time and annoys people.
• New Way (Bayesian): You start with a hunch (based on past cases). As you interview people, you update your hunch.
  • If the first 20 people all say, "The crime definitely happened," you keep going to prove it.
  • Crucially: If the first 20 people say, "The crime almost certainly didn't happen," you can stop immediately. You don't need to interview the other 80 people. You've saved them time and effort, and you still have a solid answer.

This study uses math to constantly ask: "Are we likely to find the broken nerves, or is this a dead end?" If the answer is "dead end," they stop the study early to protect the patients.

How the Study Works (Step-by-Step)

1. The Volunteers: They are recruiting people with Fibromyalgia and healthy people for comparison.
2. The Check-up: Before the big test, they ask questions about pain and use special tools to test sensitivity (like brushing the skin or using heat/cold). This is like checking the "weather report" before the storm.
3. The Main Event (Microneurography):
   • A tiny needle is placed near a nerve in the foot.
   • They zap the nerve gently to see how fast the signal travels.
   • The "Speed Bump" Test: They use a technique called Activity Dependent Slowing. Imagine a runner who gets tired and slows down after running fast. Healthy nerves slow down a specific way. The researchers are looking for nerves that slow down differently or fire signals when they shouldn't.
   • The "Tickle" Test: They gently poke the skin with a tiny hair-like filament to see if the nerve suddenly screams "PAIN!" when it shouldn't.

Why This Matters

• For Patients: It respects their time and comfort. If the study hits a dead end, they don't have to keep going through a 4-hour procedure.
• For Science: It gives a much clearer answer. If they find that these "ghost nerves" are indeed the cause of Fibromyalgia pain, it changes everything. It means doctors could stop guessing and start treating the specific broken part of the nervous system, rather than just treating the symptoms.

The Bottom Line

This study is like upgrading from a blurry, low-resolution photo of a crime scene to a high-definition, real-time video. By using smart math (Bayesian statistics) to know when to stop, they hope to find the true source of Fibromyalgia pain without overburdening the brave people helping them solve the mystery.

Technical Summary

Based on the study protocol provided, here is a detailed technical summary of the MICRO-FMS study.

1. Problem Statement

• Clinical Context: Fibromyalgia Syndrome (FMS) is a chronic pain condition affecting 2–8% of the population, characterized by widespread pain, fatigue, and cognitive dysfunction. Its etiology remains poorly understood, though evidence suggests involvement of both central and peripheral nervous systems.
• Scientific Gap: Previous microneurography studies suggest that a specific subclass of C-fibre nociceptors, known as Type 1B or mechanically-insensitive (CMi) nociceptors, exhibit abnormal spontaneous activity and mechanical sensitization in FMS patients.
• Methodological Limitation: Prior studies have been limited by small sample sizes (e.g., $n=27$), resulting in large confidence intervals around prevalence estimates. This lack of statistical precision complicates the interpretation of whether CMi hyperexcitability is a primary driver of FMS pain.
• Ethical/Practical Constraint: Microneurography is an invasive, time-consuming, and burdensome procedure for participants, carrying risks of adverse events (e.g., paraesthesia, pain). Traditional frequentist study designs often require large sample sizes to achieve power, which is often unfeasible for this technique and ethically challenging given the patient burden.

2. Methodology

The study employs an adaptive Bayesian study design combined with an optimized microneurography protocol to maximize data yield while minimizing patient burden.

A. Study Design & Population

• Participants:
  • Primary Cohort: FMS patients recruited from secondary care pain clinics (Target $N=60$).
  • Control Cohort: Age- and sex-matched healthy volunteers ($N=25$).
• Inclusion/Exclusion: Strict criteria regarding needle phobia, neurological disorders, and anticoagulant use to ensure safety during intraneural recordings.
• Adaptive Stopping Rule: The study utilizes a Bayesian predictive probability of futility. Recruitment will be terminated early if there is >95% confidence that the prevalence of spontaneous CMi activity is <20% (the threshold deemed clinically meaningful).
  • Interim analyses occur after the first 20 evaluable patients and every 10 thereafter.
  • This approach balances the risk of Type II error (false negative) against participant burden.

B. Technical Protocol: Microneurography

• Target Nerve: Superficial peroneal nerve at the lateral malleolus (dorsum of the foot).
• Recording Setup:
  • Tungsten microelectrodes (2 MΩ impedance) inserted under ultrasound guidance.
  • Differential recording using Intan RHD 2116 chip (30 kHz sampling, 300–6000 Hz bandpass).
• Fibre Identification & Classification (Optimized Workflow):
  1. Screening: Electrical stimulation to identify C-fibres.
  2. Activity-Dependent Slowing (ADS) Check: A rapid low-frequency ADS protocol is applied early to identify putative CMi fibres (slowing >1% at 0.25 Hz).
  3. Confirmation: If a fibre slows >5% during a 0.5 Hz burst and recovers >44% within 10 pulses, it is classified as a CMi fibre.
  4. Primary Outcome Assessment: Immediate assessment of spontaneous activity (defined as latency jitter >1.5% of baseline) during 0.25 Hz stimulation.
  5. Mechanical Sensitivity: Probing with a 512 mN von Frey filament to detect mechanical sensitization.
  6. High-Frequency ADS: Final characterization to confirm nociceptor identity.
• Efficiency: The protocol is designed to classify fibres and assess spontaneous activity before mechanical stimulation or high-frequency protocols, reducing the risk of electrode displacement or unit fatigue.

C. Complementary Assessments

• Quantitative Sensory Testing (QST): Performed on the contralateral foot to assess thermal/mechanical thresholds and pain sensitivity (DFNS protocol).
• Phenotyping: Patients are stratified into "irritable" vs. "non-irritable" nociceptor phenotypes based on QST results to correlate with electrophysiological findings.
• Questionnaires: Pain descriptors, impact scales, and body maps (CHOIR) to correlate subjective pain with objective electrophysiology.

3. Key Contributions

• Bayesian Adaptive Design: This is a pioneering application of Bayesian predictive probability of futility in microneurography. It allows for early termination if the hypothesis is unlikely to be true, significantly reducing the number of participants exposed to invasive procedures without compromising statistical validity.
• Optimized Electrophysiological Protocol: The study introduces a workflow where CMi classification and spontaneous activity assessment occur early in the recording session. This maximizes the yield of usable data per patient and minimizes the duration of the procedure.
• Integration of Multi-Modal Data: The protocol uniquely links direct peripheral nerve recordings (microneurography) with psychophysical QST and subjective pain reporting in the same anatomical region, addressing the gap between peripheral mechanisms and clinical symptoms.
• Patient-Centric Development: The stopping criteria and risk-benefit analysis were co-developed with a Patient and Public Involvement and Engagement (PPIE) group, ensuring the study design respects the lived experience of chronic pain patients.

4. Results (Projected/Methodological)

Note: As this is a study protocol, empirical results are not yet available. The paper presents simulation results validating the design.

• Simulation Outcomes:
  • Bayesian vs. Frequentist: Simulations ($n=10,000$) showed that the Bayesian approach correctly identifies futility in 33.3% of scenarios where the true prevalence is low (<20%), whereas a standard frequentist approach failed to identify futility in 96% of similar scenarios.
  • Prior Sensitivity: The study uses a "de-weighted" prior (Beta(1,4)) to avoid over-reliance on historical data, ensuring new data meaningfully updates the posterior probability even with small sample sizes.
  • Power: The design is robust enough to detect a prevalence of 40% (based on prior literature) while protecting against false negatives if the true prevalence is near the 20% threshold.

5. Significance

• Mechanistic Insight: If successful, the study will provide high-precision evidence regarding whether spontaneous CMi activity is a primary driver of fibromyalgia pain, potentially validating a peripheral target for therapy.
• Methodological Advancement: It establishes a new standard for conducting invasive neurophysiological research in chronic pain, demonstrating how adaptive designs can ethically and efficiently resolve scientific uncertainty.
• Clinical Stratification: By correlating electrophysiology with QST phenotypes, the study may help identify specific subgroups of fibromyalgia patients who could benefit from targeted peripheral treatments (e.g., sodium channel blockers), moving the field toward mechanism-based medicine.
• Ethical Framework: The protocol serves as a model for balancing rigorous scientific inquiry with the ethical imperative to minimize harm and burden in vulnerable patient populations.